A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor

BACKGROUND: The discovery of receptor activator of nuclear factor‐ĸB ligand (RANKL) as the final effector in the pathogenesis of osteoporosis has led to a better understanding of bone remodeling. When RANKL binds to its receptor (RANK), osteoclastic differentiation and activation are initiated. Here...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Transl Med
Asıl Yazarlar: Ko, Young Jong, Sohn, Hong Moon, Jang, Yuria, Park, Mineon, Kim, Bora, Kim, Beomchang, Park, Jae‐Il, Hyun, Hoon, Jeong, Byeongseok, Hong, Chansik, Lim, Wonbong
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2021
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7967917/
https://ncbi.nlm.nih.gov/pubmed/33784004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ctm2.368
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller